User Register / Login

Roche Natural Capital Protocol Pilot: Summary Report

March 22, 2017 |

Natural Capital Assessment of Roche’s Swiss operational sites

James Spurgeon (Sustain Value) and Christopher Earl (Roche), February 2017


As part of its commitment to sustainability, in 2015/2016 Roche1 undertook a deep dive pilot of the Natural Capital Protocol with technical support from Sustain Value2. The aim was to both help inform development of the Protocol, and to provide Roche with a better understanding of natural capital assessment (NCA) approaches and the added value their use could bring to the company.

The Protocol is a standardized nine-step framework for businesses to identify, measure and value direct and indirect impacts (both positive and negative), and dependencies, upon natural capital, using an NCA. Launched in July 2016, the Protocol is being applied by a growing number of businesses across all sectors, primarily to enhance company decision-making, but also to improve reporting.

Objectives and scope

The primary objective of the pilot NCA was to evaluate and better understand how Roche both depends and impacts upon natural capital at its six operational sites in Switzerland. Only direct operational activities were assessed, as opposed to wider value chain issues. The assessment included a mix of qualitative, quantitative and monetary valuation approaches across a range of potentially material natural capital issues. This included evaluating associated costs and benefits relating to both external stakeholders (i.e. societal values), and to the company itself (i.e. business values). Progress and outcomes were to be covered in the Roche’s 2015 and 2016 annual reports respectively.

A secondary objective was to explore how an NCA approach compares to Roche’s existing ‘Eco-balance’ approach, which is used to assess and help manage environmental impacts at a site and corporate level. In addition, a high-level assessment to identify potentially material natural capital impacts and dependencies across the company’s overall global value chain was also to be undertaken.


The study followed each of the Protocol’s nine Steps, and involved visits to each operational site, a literature review, analysis of company data and meetings with key internal company stakeholders. Core to the analysis was a review of existing Eco-balance data for each site, comprising quantitative information relating to consumption of key resource use, emissions and discharges. However, the assessment also identified other impacts and dependencies not included in the Eco-balance dataset. A total of 36 specific impact drivers and dependencies were evaluated at least qualitatively using a ‘relative value’ approach, with many also being valued in monetary terms using a ‘value transfer’ approach. The latter involved drawing heavily on monetary values determined in other similar contexts and applying them to the Swiss context, making adjustments as necessary (in accordance with guidance on the technique outlined in the Natural Capital Protocol). Due to time and data constraints, more effort was focused on assessing societal values rather than business values.

Main findings

The assessment provided numerous useful insights for Roche, including:

  • The monetary valuation approach yielded reasonably similar ‘relative’ results to the Eco-balance approach (see Figure 1), effectively validating the Eco-balance approach that Roche has been undertaking for several years.
  • The NCA approach helped to identify, quantify and value a wider range of both negative and positive impacts than addressed by the Eco-balance approach. Additional negative impacts include incinerated waste and non-greenhouse gas (GHG) impacts from employee business travel. Additional positive impacts included provision of green space, indoor plants and habitats (e.g. aquatic and terrestrial) giving rise to biodiversity, recreational, health and wellbeing benefits.

  • The monetary valuation approach allows the company and stakeholders to better understand and relate to how significant Roche’s negative impacts actually are.
  • The study has shown that whilst Roche does cause negative environmental impacts (which Roche actively manages), they do not pose a threat to Roche’s continued operation. This is because: i) their estimated value compared to net income is low; ii) the likelihood of imminent internalization is low; and iii) Roche is already actively managing and reducing its most material impacts.
  • In monetary terms, total negative impacts for the Swiss sites equate to 6.2% of Roche’s annual net Swiss income, with total GHG impacts representing 5% of annual net Swiss income. It should not be concluded that the 6.2% reflects the situation for Roche worldwide. In Switzerland Roche has a concentration of operations compared to sales. In a separate analysis we have estimated that the negative impacts worldwide account for less than 1% of sales.
  • The assessment also identified other potentially material environmental issues at the Swiss sites that Roche could benefit from considering in more detail. This included employee canteen food (sourcing, consumption and waste); management of biodiversity; and use of green space, green roofs and indoor plants to enhance staff health and wellbeing.   

Next steps

The assessment highlighted that Roche could benefit in a number of ways from adopting an NCA approach. As a result of additional insights and adopting a value-based perspective, business benefits can be gained through helping to make more sustainable and profitable decisions, creating greater shared value for staff and stakeholders, and enhancing the company’s reputation.

In addition, a number of other potential NCA applications were identified. In particular this includes i) further evaluating potential risks and opportunities related to water, food, green space, green infrastructure and biodiversity; and ii) comparing options such as alternative new building designs and decommissioning options.

A key lesson learned from the pilot was the challenge of trying to cover multiple issues at multiple sites from multiple perspectives (i.e. impacts and dependencies as well as societal and business values).

Consequently, Roche is commencing a further NCA, this time focusing solely on applying the Protocol to water at one of its Californian operational sites, where water availability is becoming a critical issue for Roche and wider stakeholders.


  1. Roche is the world’s largest Biotech company, headquartered in Switzerland, with operations in over 100 countries. 
  2. Sustain Value is a consultancy firm that specializes in helping companies quantify, value and manage natural and social capital impacts and assets. 
  3. A relative expression of value in a particular context (Natural Capital Protocol, 2016).
  4. An important point raised by the study was the fact that Roche generates considerable unaccounted for positive social value from use of their products and other socially responsible activities, which likely far outweigh any negative environmental impacts.

Benefit from the Coalition’s unique overview of the capitals approach and community, gain insights into the latest thinking and developments and receive newsletters and project updates.